Literature DB >> 29610516

Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series.

Sunhee Park1, Elisabeth Evans2, William J Sandborn2, Brigid Boland2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29610516     DOI： 10.1038/ajg.2018.22

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  4 in total

1.  Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.

Authors:  Robert Battat; Uri Kopylov; Talat Bessissow; Alain Bitton; Albert Cohen; Anjali Jain; Myriam Martel; Ernest Seidman; Waqqas Afif
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-29       Impact factor: 11.382

2.  Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.

Authors:  Christopher Ma; Richard N Fedorak; Gilaad G Kaplan; Levinus A Dieleman; Shane M Devlin; Nathan Stern; Karen I Kroeker; Cynthia H Seow; Yvette Leung; Kerri L Novak; Brendan P Halloran; Vivian W Huang; Karen Wong; Philip K Blustein; Subrata Ghosh; Remo Panaccione
Journal:  Inflamm Bowel Dis       Date:  2017-05       Impact factor: 5.325

3.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Authors:  William J Sandborn; Christopher Gasink; Long-Long Gao; Marion A Blank; Jewel Johanns; Cynthia Guzzo; Bruce E Sands; Stephen B Hanauer; Stephan Targan; Paul Rutgeerts; Subrata Ghosh; Willem J S de Villiers; Remo Panaccione; Gordon Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G Feagan
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

4.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Authors:  Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245
  4 in total
  2 in total

1.  Early real-world effectiveness of ustekinumab for Crohn's disease.

Authors:  Richard James Harris; Martin McDonnell; David Young; Marion Bettey; Louise Downey; Lucinda Pigott; Richard Felwick; Markus Gwiggner; J R Fraser Cummings
Journal:  Frontline Gastroenterol       Date:  2019-05-29

Review 2.  How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data.

Authors:  Ana Gutiérrez; Iago Rodríguez-Lago
Journal:  Front Med (Lausanne)       Date:  2021-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.